𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma

✍ Scribed by Carlo Buzio; Simeone Andrulli; Rosaria Santi; Laura Pavone; Rodolfo Passalacqua; Domenico Potenzoni; Francesco Ferrozzi; Roberto Giacosa; Augusto Vaglio

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
182 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of 5-fluorouracil, interf
Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d

High dose chemotherapy with autologous s
High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma : Long term results for 105 patients
✍ Takao Shinozuka; Tsuyoshi Miyamoto; Toshinari Muramatsu; Takeshi Hirasawa; Masar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

## BACKGROUND. In this study, the authors reviewed long term results and prognostic factors of high dose chemotherapy (HDC) with autologous stem cell support administered to 105 patients with epithelial ovarian carcinoma. ## METHODS. Prior to HDC, platinum-based chemotherapy was given to optimi

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

5-fluorouracil and low-dose recombinant
5-fluorouracil and low-dose recombinant interferon-α-2a in patients with hormone-refractory adenocarcinoma of the prostate
✍ Shinohara, Nobuo; Demura, Takayoshi; Matsumura, Kin-ya; Toyoda, Ken-ichi; Kashiw 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

## Background: The effectiveness of a chemotherapy regimen including 5-fluorouracil (5-fu) and recombinant interferon-alpha-2a (rifn-alpha-2a) was evaluated in hormone-refractory prostate cancer patients. ## Methods: Patients received a continuous intravenous infusion of 5-fu at 600 mg/m2/day for